摘要
目的比较米氮平与帕罗西汀治疗抑郁症的疗效。方法将符合CCMD-3抑郁症诊断标准的62例患者随机分为米氮平和帕罗西汀组,分别在治疗第0、1、2、4、8周以HAMD、HAMA评定疗效,副反应量表TESS评定不良反应。结果经8周治疗后,米氮平组有效率为86.1%,帕罗西汀组为83.3%,两组相比较,差异无统计学意义(P>0.05);米氮平第1周开始起效,第1周疗效两组比较,治疗前、后差异有统计学意义(P<0.01)。帕罗西汀主要不良反应为食欲下降、口干、性功能障碍等,与米氮平比较差异有统计学意义。结论米氮平对伴有焦虑症状的抑郁症有良好疗效,起效快,不良反应相对帕罗西汀少而轻。
Objective To compare the efficacy of mirtazapine with that of paroxetine. Methods 62 patients with a diagnosis of major depressive.episode （CCMD-3）were randomly assigne to 8 weeks of treatment with mirtazapine or paroxetine.Efficacy was assessed by Hamilton Depression Rating Scale. （HAMD-17 ）, Hamilton Anxiety Scale（HAMA） the end of baseline and 1,2,4,8 weeks after treatment, and the safety was assessed by Treatment Emergent Symptom Scale（TESS ）. Results After 8 weeks treatment, the significant improvement rate of mirtazapine grorp and parnxetine group were 86.1% and 83.3%, respectively（P〉0.05 ）,The efficacy started after 7 days treatment in mirtazapine group.The scores of HAMD and HAMA in two group were statisticral deference before and after treatment（P〈0.01 ）. The main adverse reactions were lack of appetite,dry mouth,sexual dysfunction. Conclusion Mirtazapine had good effectiveness in the depressed patients with anxiety symptoms.Mirtazapin has less side effects, better safety and rapid response comparred with paroxetine suiting for clinical use.
出处
《中国现代医生》
2009年第34期38-39,44,共3页
China Modern Doctor
关键词
抑郁症
米氮平
帕罗西汀
Depression
Mirtazapine
Paroxetine
